Loading…
Loading…
CWBR (CohBar, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
MENLO PARK, Calif.--(BUSINESS WIRE)--On November 20, 2023, CohBar, Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) of its determination pursuant to Nasdaq Listing Rule 5101 that, based upon the Staff's belief that the Company is a “public shell,” and that the continued listing of the Company's securities is no longer warranted, and the Company's non-compliance with certain board and committee composition listing.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of CohBar, Inc. (the “Company”) (NasdaqCM: CWBR) with Morphogenesis, Inc. pursuant to which CohBar shareholders will end up owning approximately 15% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
MENLO PARK, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) today reported its financial results and highlights for the second quarter ended June 30, 2023.
MILWAUKEE, May 24, 2023 /PRNewswire/ — Ademi LLP is investigating CohBar (NASDAQ: CWBR) for possible breaches of fiduciary duty and other violations of law in its transaction with Morphogenesis, Inc. Click here to learn how to join the action https://www.ademilaw.com/case/cohbar-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. CohBar public stockholders […]...
CohBar (NASDAQ: CWBR ) stock is soaring higher on Tuesday after the company announced a planned merger with Morphogenesis . CohBar and Morphogenesis are planning for an all-stock merger that will see the two combine to create a new company named “TuHURA Biosciences, Inc.” This company will continue to trade its shares on The Nasdaq Capital Market.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of CohBar, Inc. (NASDAQ: CWBR) and Morphogenesis, Inc. is fair to CohBar shareholders. Halper Sadeh encourages CohBar shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether CohBar and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for CohBar shareholders; and (2) disclose all material information necessary for CohBar shareholders to adequately assess and value the merger consideration. On behalf of CohBar shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. Halper Sadeh encourages CohBar shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
Cohbar Inc. (CWBR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
No recent filings indexed.